E
NBSE

Ergoteles’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Ergoteles’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,895
Closed -$7.21K – 1890
2022
Q4 		$7.21K Buy
+1,895
New +$9.72K ﹤0.01% 1378
2021
Q4 		– Sell
-3,728
Closed -$269K – 1676
2021
Q3 		$269K Sell
3,728
-105
-3% -$8.04K 0.01% 853
2021
Q2 		$367K Buy
+3,833
New +$423K 0.01% 964

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's NBSE Position: Q1 2023 in Review

Ergoteles sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2023, closing a stake of 1,895 shares — an estimated $7.21K sold.

Ergoteles first reported a position in NBSE in Q2 2021 and held it in 3 quarters. The position peaked at $367K in Q2 2021. 35 funds tracked by Wall St. Rank hold NBSE as of Q1 2023.

  • Ergoteles reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 1,895 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $7.21K.
  • Ergoteles first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Ergoteles's NeuBase Therapeutics, Inc. Common Stock position peaked at $367K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.